While the drug is not a cure, researchers say it could meaningfully improve both the length and quality of life for patients with advanced disease. | World News

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.